An interventional study of Transdiagnostic metacognitive therapy and Disorder-specific cognitive-behavioral therapy in Generalized Anxiety Disorder, Social Anxiety Disorder and Posttraumatic Stress Disorder (PTSD), sponsored by Karolinska Institutet. Recruiting at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-18.
Sponsored by Karolinska Institutet · Not applicable, Interventional, and Treatment
This is a qualitative study of participants who have taken part in a randomized controlled trial comparing transdiagnostic metacognitive therapy and disorder-specific cognitive-behavioral therapy for anxiety disorders. The purpose of the study is to explore participant perceptions of the respective treatment models to facilitate implementation and dissemination of the treatments.
517 studies on the registry are indexed under Generalized Anxiety Disorder; 124 are open to participants now.
This study's planned enrollment of 30 is below the median of 83 across 439 interventional studies indexed under Generalized Anxiety Disorder.
Browse Generalized Anxiety Disorder studies →Karolinska Institutet is the lead sponsor of 1,148 studies on the registry; 276 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Metacognitive therapy in a transdiagnostic format; a single treatment protocol is used for all three anxiety disorders
Behavioral: Transdiagnostic metacognitive therapy
Cognitive-behavioral therapy in a disorder-specific format; each of the three anxiety disorders is treated using a separate treatment protocol
Behavioral: Disorder-specific cognitive-behavioral therapy
Metacognitive therapy focuses on metacognitions.
Cognitive-behavioral therapy focuses on cognitions and/or behaviors.
Qualitative interview data
Participant responses based on questions posed in an interview
Time frame: Up to 13 weeks
Plan to share: Yes — The datasets analyzed in this study are not publicly available due to legal and ethical restrictions under Swedish data protection regulations. Requests for access may be directed to the Data Protection Officer at Stockholm Health Care Services, and are subject to approval by the relevant data governance authorities. Requests to access the datasets should be directed to gdpr.slso@regionstockholm.se.
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.
Of 174 non-industry interventional studies with no phase under Generalized Anxiety Disorder, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 55. This study's planned 11 months is below that.
Counting every sponsor, half of 183 studies reached it within 28 months; a quarter within 15 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Generalized Anxiety Disorder →